Ten patients had baseline magnetic resonance imaging (MRI) scans and seven had follow-up MRI scans; the remainder had no clinical relapses during the follow-up period. The control group consisted of 17 patients with other noninflammatory neurological diseases. Isoelectric focusing for detection of intrathecal IgG was performed in all of the control patients and none had oligoclonal bands. Blood samples were collected, spun down and stored in 2-mL aliquots at (/708C. Coded samples were analysed for the presence of MSRV as described. 9 The previously defined cut-off for a positive test was an optical density (OD) above 0.8. Plasma S100B and GFAP were measured using standard ELISA systems with a sensitivity of 0.04 ng/mL and 5 pg/mL, respectively. 10, 11 Statistical analysis was performed using Fisher's exact test for categorical variables and the nonparametric Kruskal Á/Wallis test for continuous variables.
The patients were younger (median 32 years, range 30 Á/41) compared to the control population (51, 37 Á/61), but there was no difference in age between those who developed clinically definite MS according to the Poser criteria (CDMS) (27, 32 Á/31) and those who did not (33, 31 Á/41). The median follow-up time was 12 months (range 5 Á/42). As reported previously, 8 only two patients developed CDMS. In another two patients the MRI showed new lesions separated in time and space, thus satisfying the MacDonald criteria. 12 However, none of the patients had evidence of MSRV infection, unlike two of the controls. There was no difference in the median OD, between the Poser-positive and the MacDonald-positive patients.
The glial proteins S100B and GFAP were not found to be elevated in the plasma of these patients. This may in part be related to the assays' sensitivity.
In contrast to the Sardinian cohort and cell lines from previously reported cohorts, this study investigated for the first time the presence of MSRV in patients with acute ON.
1,2,5 The working hypothesis that some patients with ON might have been MSRV carriers with active virion recirculation (viraemia) and have a higher risk of developing MS could not be proven. Interestingly, the Sardinian group described infection with MSRV also in a significantly higher proportion of patients with other inflammatory diseases (63.6%) when compared to healthy blood donors (12.8%). 5 We agree with these authors that infection with MSRV might merely represent an epiphenomenon, 5 but the very particular type of retroviral agent, belonging to a family of endogenous human retroviruses, HERV-W, raises much more complex questions. 13 The fact that ON patients did not have a viraemia on their first symptomatic manifestation does not preclude them from carrying the MSRV genome in their cells: it may be that it was not expressed prior to and during the onset phase of ON. Further studies should therefore be extended to patients who went on to develop MS, to investigate whether they then had an MSRV viraemia. Such a study has the potential to provide a valuable insight into the possibility that ON could be caused by another infectious agent or environmental factor, which triggers MSRV reactivation in susceptible carriers, as suggested by experimental data on MSRV transactivation.
14 Whether this could be a condition for the late evolution towards MS in such cases would also require follow-up studies with controls who have not developed MS after acute ON.
This study cannot, however, contribute to the question of whether MSRV might additionally contribute to gliotoxicity because none of the ON patients had MSRV viraemia.
